title: T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
abstract: To determine the effects of high-dose intravenous methylprednisolone (MP) on lymphocytes and lymphocyte subpopulations in the cerebrospinal fluid (CSF) and peripheral blood (PB) in multiple sclerosis (MS) patients, we studied 67 patients with definite MS treated with MP. They were classified according to the disease course: 32 chronic progressive (CP) patients, 25 relapsing-remitting (RR) patients, and 10 patients with a chronic progressive disease course accompanied by relapses and remissions (CP + RR). MS patients were treated with 1000 mgr intravenous MP daily for 10 consecutive days. Before and after MP treatment we simultaneously studied CSF and PB CD3+, CD4+, CD8+, CD20+, and Ia1+ cell subsets. Kurtzke's Expanded Disability Status Scale (EDSS) was used for clinical evaluation. Progression rate was defined as the ratio of EDSS to disease duration. Thirteen patients with lumbar disk herniation were investigated as controls. Before MP, we found in MS patients, especially in the CP group, significantly lower CD4+ T-cell percentages in the PB with respect to controls (p < 0.05). The percentage of CD4+ T-cells in the CSF of MS patients was significantly higher compared with PB (p = 0.0001), and tended to be higher than in controls (p = 0.072). The CSF mononuclear cell counts were significantly correlated with higher percentages of CSF CD3+ (r = 0.40) and CD4+ (r = 0.47) T-cells and lower CSF CD8+ (r = -0.33) T-cell percentages. B-cell percentages in the CSF were significantly elevated compared with controls for all MS groups. No relation could be obtained between T- or B-cell subsets and EDSS or progression rate.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Neurology, University Hospital, Amsterdam, The Netherlands.
authors.forename: S T
authors.initials: ST
authors.lastname: Frequin
authors.forename: K J
authors.initials: KJ
authors.lastname: Lamers
authors.forename: G F
authors.initials: GF
authors.lastname: Borm
authors.forename: F
authors.initials: F
authors.lastname: Barkhof
authors.forename: P J
authors.initials: PJ
authors.lastname: Jongen
authors.forename: O R
authors.initials: OR
authors.lastname: Hommes
mesh_terms: D000305:Adrenal Cortex Hormones / Q000502:physiology; D000328:Adult; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D002555:Cerebrospinal Fluid / Q000737:chemistry / Q000187:drug effects* / Q000276:immunology; D002908:Chronic Disease; D003711:Demyelinating Diseases; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007405:Intervertebral Disc Displacement / Q000188:drug therapy; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
chemical_list: D000305:Adrenal Cortex Hormones; D008775:Methylprednisolone